Volume 25, Number 7—July 2019
Synopsis
Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015
Table 4
Antimicrobial agent | No. susceptible/total no. tested (%) | Epidemiologic classification, no. susceptible/total no. tested (%)* |
p value | |
---|---|---|---|---|
Healthcare-associated | Community-associated | |||
Cephalosporins | ||||
Any cephalosporin | 181/275 (65.8) | 153/241 (63.5) | 18/21 (85.7) | 0.04 |
Ceftazidime | 101/151 (66.9) | 89/136 (65.4) | 6/6 (100) | 0.18† |
Cefepime |
146/273 (53.5) |
120/239 (50.2) |
17/21 (81.0) |
0.01 |
Aminoglycosides | ||||
Any aminoglycoside | 246/276 (89.1) | 212/241 (88.0) | 21/21 (100) | 0.14† |
Amikacin | 203/237 (85.7) | 179/213 (84.0) | 17/17 (100) | 0.08† |
Gentamicin | 162/268 (60.5) | 134/234 (57.3) | 17/20 (85.0) | 0.02 |
Tobramycin |
118/180 (65.6) |
104/164 (63.4) |
7/7 (100) |
0.10† |
Fluoroquinolones | ||||
Any fluoroquinolone | 96/274 (35.0) | 74/240 (30.8) | 16/20 (80.0) | <0.01 |
Ciprofloxacin | 93/266 (35.0) | 71/233 (30.5) | 16/19 (84.2) | <0.01 |
Levofloxacin |
29/142 (20.4) |
23/128 (18.0) |
3/5 (60.0) |
0.05† |
Other antimicrobials | ||||
Aztreonam | 63/168 (37.5) | 46/146 (31.5) | 12/15 (80.0) | <0.01 |
Piperacillin/tazobactam |
134/266 (50.4) |
106/231 (45.9) |
19/21 (90.5) |
<0.01 |
Resistance |
No. multidrug-resistant/total no. tested (%) |
|||
Multidrug-resistant isolates‡ | 181/268 (67.5) | 167/234 (71.4) | 4/20 (20.0) | <0.01 |
*Antimicrobial susceptibilities by epidemiologic classification are restricted to the 281 incident cases with a completed case report form. Healthcare-associated is defined as a case with >1 healthcare risk factor reported; community-associated is defined as a case with no healthcare risk factors reported.
†By Fisher exact test.
‡Defined as an isolate resistant to 1 carbapenem (doripenem, imipenem, meropenem) and nonsusceptible to >1 antimicrobial drug in >2 of the following classes: cephalosporin (ceftazidime, cefepime), aminoglycoside (amikacin, gentamicin, tobramycin), fluoroquinolone (ciprofloxacin, levofloxacin), β-lactamase inhibitor combination (piperacillin-tazobactam), and monobactam (aztreonam).
Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.